Back to results

Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography

Primary Purpose

Liver Disease

Status

Unknown status

Phase

Phase 4

Locations

Taiwan

Study Type

Interventional

Intervention

morphine and glucagon

About this trial

This is an interventional diagnostic trial for Liver Disease

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: normal volunteer living liver donor Exclusion Criteria: COPD chronic liver disease hypersensitive to glucagon DM insulinoma glucagonoma pregnancy

Sites / Locations

National Taiwan University HospitalRecruiting

Outcomes

Primary Outcome Measures

MRCP visibility

Secondary Outcome Measures

Full Information

NCT ID

NCT00155376

First Posted

September 8, 2005

Last Updated

November 25, 2005

Sponsor

National Taiwan University Hospital

1. Study Identification

Unique Protocol Identification Number

NCT00155376

Brief Title

Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography

Study Type

Interventional

2. Study Status

Record Verification Date

April 2005

Overall Recruitment Status

Unknown status

Study Start Date

September 2005 (undefined)

Primary Completion Date

undefined (undefined)

Study Completion Date

September 2005 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor

National Taiwan University Hospital

4. Oversight

5. Study Description

Brief Summary

Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.

Detailed Description

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Liver Disease

7. Study Design

Primary Purpose

Diagnostic

Study Phase

Phase 4

Interventional Study Model

Parallel Assignment

Masking

Double

Allocation

Randomized

Enrollment

100 (false)

8. Arms, Groups, and Interventions

Intervention Type

Drug

Intervention Name(s)

morphine and glucagon

Primary Outcome Measure Information:

Title

MRCP visibility

10. Eligibility

Sex

All

Minimum Age & Unit of Time

20 Years

Maximum Age & Unit of Time

75 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: normal volunteer living liver donor Exclusion Criteria: COPD chronic liver disease hypersensitive to glucagon DM insulinoma glucagonoma pregnancy

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Yuan-Heng Mo, MD

jamesmyh@ha.mc.ntu.edu.tw

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Hon-Man Liu, MD

Organizational Affiliation

National Taiwan University Hospital

Official's Role

Study Chair

Facility Information:

Facility Name

National Taiwan University Hospital

City

Taipei

State/Province

province of Taiwan

ZIP/Postal Code

100

Country

Taiwan

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Yuan-Heng Mo, MD

jamesmyh@ha.mc.ntu.edu.tw

12. IPD Sharing Statement

Learn more about this trial

Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography

We'll reach out to this number within 24 hrs